Verrica Property Plant Equipment vs Short Term Debt Analysis
VRCA Stock | USD 0.85 0.07 7.61% |
Verrica Pharmaceuticals financial indicator trend analysis is much more than just breaking down Verrica Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verrica Pharmaceuticals is a good investment. Please check the relationship between Verrica Pharmaceuticals Property Plant Equipment and its Short Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.
Property Plant Equipment vs Short Term Debt
Property Plant Equipment vs Short Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verrica Pharmaceuticals Property Plant Equipment account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Verrica Pharmaceuticals' Property Plant Equipment and Short Term Debt is 0.59. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Verrica Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Verrica Pharmaceuticals' Property Plant Equipment and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Verrica Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Property Plant Equipment i.e., Verrica Pharmaceuticals' Property Plant Equipment and Short Term Debt go up and down completely randomly.
Correlation Coefficient | 0.59 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Property Plant Equipment
Short Term Debt
Most indicators from Verrica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verrica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 2.30, whereas Selling General Administrative is forecasted to decline to about 17.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 472K | 718K | 836K | 464.2K | Interest Income | 123K | 476K | 2.2M | 2.3M |
Verrica Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Verrica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verrica Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 68.4M | 74.2M | 80.1M | 44.7M | 81.6M | 62.0M | |
Other Current Liab | 2.0M | 3.1M | 3.3M | 2.7M | 13.9M | 14.6M | |
Total Current Liabilities | 3.4M | 39.5M | 46.1M | 3.5M | 17.0M | 15.5M | |
Total Stockholder Equity | 65.0M | 33.0M | 32.6M | 40.0M | 19.8M | 39.3M | |
Net Tangible Assets | 65.0M | 33.0M | 32.6M | 40.0M | 46.0M | 39.3M | |
Net Debt | (9.1M) | 24.6M | 27.7M | (32.7M) | (24.0M) | (25.2M) | |
Retained Earnings | (61.2M) | (103.9M) | (139.0M) | (163.5M) | (230.4M) | (218.9M) | |
Accounts Payable | 1.2M | 348K | 845K | 507K | 2.5M | 2.6M | |
Cash | 9.2M | 10.7M | 15.8M | 34.3M | 69.5M | 73.0M | |
Non Current Assets Total | 3.4M | 8.7M | 5.8M | 5.6M | 4.1M | 4.1M | |
Non Currrent Assets Other | 830K | 3.7M | 295K | 276K | 452.0K | 429.4K | |
Cash And Short Term Investments | 62.0M | 65.5M | 70.4M | 34.3M | 69.5M | 55.1M | |
Common Stock Shares Outstanding | 24.9M | 25.0M | 27.0M | 34.2M | 45.3M | 29.0M | |
Liabilities And Stockholders Equity | 68.4M | 74.2M | 80.1M | 44.7M | 81.6M | 62.0M | |
Non Current Liabilities Total | 58K | 35.3M | 1.5M | 1.2M | 44.8M | 47.1M | |
Capital Surpluse | 126.6M | 136.9M | 171.6M | 203.5M | 234.0M | 120.4M | |
Other Current Assets | 3.0M | 2.2M | 4.0M | 4.8M | 2.5M | 2.5M | |
Other Stockholder Equity | 126.2M | 136.9M | 171.6M | 203.5M | 250.2M | 128.8M | |
Total Liab | 3.4M | 41.2M | 47.5M | 4.7M | 61.8M | 64.9M | |
Total Current Assets | 65.0M | 65.5M | 74.3M | 39.1M | 77.5M | 57.9M | |
Net Invested Capital | 65.0M | 68.3M | 74.3M | 40.0M | 62.6M | 64.1M | |
Net Working Capital | 61.6M | 28.2M | 28.3M | 35.7M | 60.5M | 48.9M | |
Property Plant And Equipment Net | 2.2M | 4.9M | 5.8M | 5.6M | 3.6M | 4.1M | |
Other Assets | 1.2M | 1.6M | 295K | 276K | 1.0 | 0.95 | |
Retained Earnings Total Equity | (61.2M) | (103.9M) | (139.0M) | (163.5M) | (147.1M) | (154.5M) | |
Property Plant And Equipment Gross | 2.2M | 4.9M | 5.8M | 6.0M | 4.8M | 4.4M | |
Property Plant Equipment | 2.2M | 4.9M | 3.9M | 3.9M | 4.5M | 3.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.68) | Revenue Per Share 0.198 | Quarterly Revenue Growth 27.445 | Return On Assets (0.71) | Return On Equity (20.60) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.